Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EE Mitogen-activated protein kinase (MEK) inhibitors
L01EE01 Trametinib
D10176 Trametinib dimethyl sulfoxide (JAN/USAN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Multitargeted Kinase Inhibitors, BRAF
Trametinib
D10176 Trametinib dimethyl sulfoxide (JAN/USAN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D10176 Trametinib dimethyl sulfoxide (JAN/USAN)
Drug groups [BR:br08330]
Antineoplastic
DG03137 MEK inhibitor
DG00723 Trametinib
D10176 Trametinib dimethyl sulfoxide
Drug classes [BR:br08332]
Antineoplastic
DG03137 MEK inhibitor
D10176 Trametinib dimethyl sulfoxide
Target-based classification of drugs [BR:br08310]
Protein kinases
Serine/threonine kinases
STE group
MAP2K1 (MEK1)
D10176 Trametinib dimethyl sulfoxide (JAN/USAN) <JP/US>
MAP2K2 (MEK2)
D10176 Trametinib dimethyl sulfoxide (JAN/USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10176
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10176
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10176
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10176
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D10176
Drug groups [BR:br08330]
Antineoplastic
DG03137 MEK inhibitor
DG00723 Trametinib
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EE Mitogen-activated protein kinase (MEK) inhibitors
L01EE03 Binimetinib
D10604 Binimetinib (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
MAPK/ MEK Inhibitors
Binimetinib
D10604 Binimetinib (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D10604 Binimetinib (JAN/USAN/INN)
Drug groups [BR:br08330]
Antineoplastic
DG03137 MEK inhibitor
D10604 Binimetinib
Drug classes [BR:br08332]
Antineoplastic
DG03137 MEK inhibitor
D10604 Binimetinib
Target-based classification of drugs [BR:br08310]
Protein kinases
Serine/threonine kinases
STE group
MAP2K1 (MEK1)
D10604 Binimetinib (JAN/USAN/INN) <JP/US>
MAP2K2 (MEK2)
D10604 Binimetinib (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10604
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10604
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10604
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10604
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D10604